Objectives: This study explores the relationship of lymph node ratio (LNR) and radiotherapy (RT) to overall survival (OS) for patients with resected pancreatic cancer. The impact of adjuvant RT, number of lymph nodes (LN) resected, positive LN resected, and disease extension was also evaluated.
P ancreatic cancer remains largely fatal despite aggressive trials of surgical resection and/or multimodality adjuvant therapies. Surgical resection is considered the best potentially curative treatment but can be offered to only 15% to 20% of the diagnosed population. 1 Despite surgical resection, local failure rates may be as high as 50% to 80%. 2 The role of adjuvant radiotherapy (RT) after surgical resection in pancreatic cancer remains controversial due to lack of proven survival benefit. In particular, the ESPAC trial suggested a detrimental effect of adjuvant chemoradiotherapy; however, the validity of these findings has been questioned due to what was considered by some to be poor trial design. [3] [4] [5] A nonstatistically significant increase in 2-year overall survival (OS) was seen in the EORTC trial with the addition of concurrent RT and 5-FU in the subset of patients with pancreatic cancers. 6 In addition, retrospective single-institutional reviews have suggested a benefit to adjuvant RT and chemotherapy. 7, 8 This benefit was evident in the above studies despite more adverse prognostic factors within the adjuvantly treated population. Adjuvant therapy (RT and chemotherapy combined) was found to be beneficial in the presence of extensive disease, high histologic grade, and involved regional lymph nodes (LN). 7 Surgical series have addressed the benefit of a standard versus extended LN resection and, separately, the impact of the lymph node ratio (LNR), the ratio of involved nodes to nodes resected, in respect to patient survival. [9] [10] [11] The aforementioned studies detected a possible advantage in an extended LN dissection and in patients with a decreased LNR. LN status, however, was not evaluated in the setting of adjuvant RT.
Our study explores the relationship of the LNR on outcomes in patients receiving adjuvant RT compared with those not receiving adjuvant RT. The primary goal is to assess the impact of adjuvant RT in pancreatic cancer in relationship to the LNR. The secondary goals include separately assessing the impact of adjuvant RT, total number of LN resected, absolute number of positive resected LN, and the extension of disease in pancreatic cancer on clinical outcomes.
MATERIALS AND METHODS
The Surveillance, Epidemiology, and End Results (SEER) Registry Data provides incidence and survival data as well as patient, tumor, and treatment variables from specific geographic areas representing 28% of the US population. 12 The SEER 17 Limited Use database was queried for patients with adenocarcinoma of the pancreas from 1998 to 2006. The search was limited to patients having undergone surgical resection and pathologic examination of the specimen and regional LN. Patients were further limited to those with only local or local/regional disease (no distant metastatic sites) and a survival time of Z2 months. Patients who survived < 2 months were excluded from the data set to prevent a bias for OS in the RT arm. 13 From the patients selected, the search was further limited to patients who had known radiation status. Chemotherapy use in this disease site is not captured in the SEER database.
Data collected for each patient included patient demographics (region of the SEER registry, race/ethnicity, sex, age at presentation, year of diagnosis), tumor characteristics (Tstage, extension of disease, number of excised LN, number of positive LN), and treatment modality (status of adjuvant RT, type of radiation, sequence of radiation). LNR is defined as the number of positive LNs divided by the total number of LNs excised and is reported as a percentage (ie, percent of positive LNs). T-stage was only reported for years 2004 and later. Variations in the American Joint Committee on Cancer (AJCC) Staging Manuals with new editions limited the subgrouping in the collected patient time period to T1/T2 versus T3/T4. 14 Each patient's extent of local-regional disease was extracted directly from the SEER database for patients after 2000. For patients from 1998 to 2000, local-regional extent of disease was derived from extent of the primary tumor and LN status. All patients' extent of disease were normalized to the "Derived SS2000" definition currently in use by the SEER database regardless of the patient's year of diagnosis. 15 The primary outcome is OS, defined as the time from surgery until death, or the last date known to be alive. Cox proportional hazards (PHs) regression models were used to determine whether specific variables were related to OS. The PH assumption was tested and assumed to be appropriate if the P-value was > 0.05. When the assumption was violated (Pr0.05), graphical approaches were used to determine the extent of the violation. For continuous variables and multivariable models, the graphical approach involved plotting the scaled residuals against time to see whether the smoothingspline fit has a slope near 0. For binary variables (eg, RT), the log of the empirically estimated hazard rate per group was estimated over time per group. These estimates were then combined to generate a hazard ratio (HR) over time. A plot of the empirical HR versus time allowed us to assess the severity of the violation of the PH assumption. Those variables that violated the assumption (yet did not have crossing hazards) were compared using logrank tests instead of Cox regression. On the basis of the above-described approaches, we determined that the PH assumption was not met for RT. As a result, separate Cox models were fit for patients who received RT and for those patients who did not.
Multivariable analyses represent the measures of association between risk factors and OS adjusting for other risk factors. That is, the results are determined based on a multivariable Cox regression model with multiple predictors included in the model simultaneously. On the basis of the univariate results, risk factors are included in the multiple regression model. Because of the violation of PHs for OS as a function of RT, separate models are estimated in the patients who did and did not receive RT. Extent of disease is collapsed into local versus regional. Number of positive LNs, age at diagnosis, and year of diagnosis are treated as continuous variables (HRs represent a 1-unit increase). LNR is treated as categorical, as defined above with 0 as the reference category. Number of LN excised is also categorical with Z12 LN resected is compared with a reference of <12 LN.
RESULTS

Patient Characteristics
Patient characteristics are displayed in Table 1 . A total of 3314 patients were identified: 1597 treated with adjuvant RT and 1717 without adjuvant RT. Of the patients having received RT, 1561 patients were treated with external-beam RT, 27 with RT not otherwise specified, 6 with a combination of externalbeam RT and implants/radioisotopes, and 3 patients with radioisotopes. The sequence was RT after surgical excision in 1486 patients, before surgery in 74 patients, intraoperatively in 13 patients, RT before and after surgery in 7 patients, intraoperatively plus an additional form of delivery in 8 patients, and 9 patients unknown. Patients were categorized by LNR as delineated in the Hopkins surgical review. 11 N0 disease was classified as 0%. Positive nodal disease was further stratified as: 1% to 19%, 20% to 40%, and >40%. Of the 3314 patients in the study, 39% had LNR of 0%, 28% had LNR between 1% and 19%, 16% had LNR between 20% and 40%, and 17% had LNR > 40%. Patients who received RT tended to be younger, and also tended to have more locally advanced T-stage and LN involvement compared with patients who did not receive RT.
OS
At the time of analysis, 2221 patients had died. The median survival time for all patients was 17 months. Median survival for patients having surgery alone was 14 months Year of diagnosis 1998 75 (4) 97 (6) 1999 84 (5) 88 (6) 2000 182 (11) 206 (13) 2001 211 (12) 210 (13) 2002 200 (12) 199 (12) 2003 202 (12) 193 (12) 2004 241 (14) 220 (14) 2005 286 (17) 210 (13) 2006 236 (14) 174 (11) (1-y survival 58.1%, 2-y survival 33.6%), whereas median survival for patients having adjuvant RT was 19 months (1-y survival 73.5%, 2-y survival 41.4%), P < 0.001 ( Fig. 1 ).
Univariate Analysis
Univariate analyses are based on Cox regression models in which only 1 predictor is included in the model and, as a result, represent unadjusted HRs. Univariate analysis showed statistically significant positive associations between time to death and stage [T3/T4 vs. T1/T2: HR = 1.57; 95% confidence interval (CI), 1.26-1.95; P < 0.001], number of positive LNs (HR = 1.06 per LN; 95% CI, 1.05-1.08; P < 0.001), and extension of disease (HR = 1.42; 95% CI, 1.28-1.57; P < 0.001) compared with local-only disease. Significant negative associations were found with earlier year of diagnosis (HR = 0.95 per each year; 95% CI, 0.93-0.98; P < 0.001) and number of LN resected (HR = 0.99 per LN; 95% CI, 0.99-1.00; P = 0.005). The number of LN resected was also analyzed at a discrete cutpoint of <12 versus Z12 resected, as previously tested in the surgical literature, 11 and this was found to be significant in favor of a more complete resection (HR = 0.87; 95% CI, 0.79-0.94; P = 0.001). LNR divided into the discrete groupings defined above was also found to be significantly related to OS (P < 0.001). Age was found to be significantly related to OS (P < 0.001) with older patients having a higher risk of death.
Factors not found to be statistically significant for OS included: race (P = 0.6), region of the country (P = 0.7), and sex of patient (P = 0.2).
The relationship between RT and LNR was examined by estimating the effect of LNR on OS separately within RT patients and patients not receiving RT (Fig. 2) . Patients with a ratio of 0 were used as the reference group. For patients receiving RT, as the ratio of involved LN increased, the risk of death also increased. Patients with 1% to 19% involvement had an 18% increased risk of death (HR = 1.18; 95% CI, 1.01-1.38; P = 0.03), patients with 20% to 40% involvement had a 60% increased risk of death (HR = 1.60; 95% CI, 1.35-1.90; P < 0.001), and patients with >40% involvement had a 78% increased risk of death (HR = 1.78; 95% CI, 1.49-2.12; P < 0.001). For patients not receiving RT, as the ratio of involved LN increased, the risk of death also increased. Patients with 1% to 19% involvement had a 75% increased risk of death (HR = 1.75; 95% CI, 1.51-2.03; P < 0.001), patients with 20% to 40% involvement had a 76% increased risk of death (HR = 1.76; 95% CI, 1.47-2.10; P < 0.001), and the risk of death in patients with >40% involvement was 2.25 times higher than those with no involvement (HR = 2.25; 95% CI, 1.92-2.64; P < 0.001).
Extent of disease was originally determined to fall into one of 4 categories for all patients: (1) local disease and negative LN (14%); (2) regional extension with negative LN (25%); (3) local disease with involved LN (10%); and (4) regional extension and involved LN (51%). For estimating HRs, the local disease and negative LN category was used as the reference group (Fig. 3 ). For patients receiving RT, extension of disease was significantly related to OS (P < 0.001). Specifically, having LN involvement with either local disease or regional disease was significantly worse than local disease only. Patients with local disease and LN involvement had a 42% increased risk of death (HR = 1.42; 95% CI, 1.09-1.86; P = 0.01), and patients with regional disease and LN involvement had a 60% increased risk of death (HR = 1.60; 95% CI, 1.29-1.98; P < 0.001). Having regional disease only (no LN involvement) was not significantly different from having local disease only (HR = 1.17; 95% CI, 0.93-1.49; P = 0.20).
For patients who did not receive RT, any extension of disease (local with LN, regional only, regional with LN) was significantly worse than local-only involvement. The risk of death in patients with local plus LN involvement was 2.27 times higher than the risk of death in patients with local extension and no LN involvement (HR = 2.27; 95% CI, 1.77-2.90; P < 0.001). Regional-only extension had a 71% increased risk of death (HR = 1.71; 95% CI, 1.40-2.09; P < 0.001), and the risk of death in patients with regional plus LN involvement was 2.72 times higher than those with local extension only (HR = 2.72; 95% CI, 2.26-3.28; P < 0.001). Multivariable Analysis Table 2 reveals the results of the multivariable analyses. Among patients who did not receive RT, significant associations with OS were found for number of LN resected, LNR, year of diagnosis, regional extent of disease, and age at diagnosis. Number of positive LN was not significantly related to OS after adjusting for the other variables. Among the patients having received adjuvant RT, there were significant associations between OS and number of LN resected, number of positive resected LN, LNR, and age at diagnosis. Extent of disease and year of diagnosis were not found to be associated with OS in patients who received RT after adjusting for other factors.
DISCUSSION
For pancreatic cancer, median OS rates with surgical resection alone have ranged from 11 16 to 20.2 months 17 and 5-year OS rates from 5% to 11.5%. [16] [17] [18] Pancreatic cancer has a high propensity to fail locally. In a trial of pancreatic adenocarcinoma treated with resection, (85% R0 and 15% R1 margins), 41% had local recurrence. 18 In a retrospective analysis of 78 patients having died after macroscopic curative resection for pancreatic cancer, receiving neither RT nor chemotherapy, 71.8% of patients had a local recurrence as a component of their pattern of failure. 19 Although the presence or absence of LN metastases has been known to be an important prognostic factor, few studies have addressed the LNR. The earliest and largest series reviewing these data originates from Johns Hopkins University School of Medicine where 905 patients having had pancreaticoduodenectomy were retrospectively reviewed to evaluate LNR as a prognostic factor. 11 The median number of nodes evaluated was 17. The majority of patients, 79.3%, had positive LN. Patients with LN metastases had a shorter median OS (16.5 mo) compared with patients with negative LN (25.3 mo). In reviewing LN data, LNR was the most compelling predictor of survival. As the LNR increased from 0%, >0% to < 20%, 20% to 40% to >40%, the median OS decreased. LNR remained an independent predictor of OS even after adjusting for other factors. This same study demonstrated that the number of LNs resected (< 12 vs. Z12) tended to be associated with a worse prognosis in N0 patients. This did not manifest as a prognostic factor in N1 patients (although virtually all patients with N1 disease received some form of adjuvant therapy). This suggests that patients receiving dissection of <12 LN may be understaged. Adjuvant therapy, such as RT delivery and dose, was not analyzed as a potential prognostic factor. In a later analysis by researchers at Johns Hopkins, the pattern of recurrence was reviewed for 154 of the 905 patients previously assessed. 2 A heterogenous course of RT concurrent with 5-FU had been given based on institutional protocol from 1995 to 2005. The RT dose ranged from 34 to 57 Gy delivered in fractionated doses of 1.8 to 2.4 Gy. A portion of the patients had a 2-week break incorporated into the treatment. Among risk factors for local recurrence was the presence of metastatic LNs. Among N1 patients, >5 metastatic LN and an LNR of >40% had the highest risk of local recurrence. Increasing LNR was associated with an incremental increased risk of local recurrence. An analysis of local failure and radiation dose found no association. The SEER data set was comprehensively evaluated for the impact of RT as adjuvant therapy in resectable pancreatic cancer by Hazard and colleagues. However, this analysis only included patients from 1988 to 2002 and did not evaluate the impact of LNR. Forty-two percent of these patients received RT, and RT demonstrated a statistically significant improvement in OS as compared with no RT. In multivariable analysis, RT was associated with an improvement in OS in patients with either LN-positive disease and/or direct extension but not in patients with T1-T2N0M0 disease. 13 In a secondary analysis of RTOG 9704, the influence of LN factors (number of positive nodes, total nodes examined, and LNR) was assessed in regard to OS and disease-free survival (DFS). A higher number of positive LN was associated with worse OS and DFS. In multivariable analyses, both the number of positive LN and total nodes examined were associated with OS and DFS. Total nodes examined >12 and >15 were associated with increased OS for all patients. This, however, did not hold true for node-negative patients. Increased LNR was associated with worse OS and DFS. 20 Our study of 3314 patients from the 1998 to 2006 SEER database shows a significant benefit from adjuvant RT after resection for pancreatic cancer, despite the fact that patients who received RT tended to have more advanced disease. Among patients who did not receive RT, significant associations with OS were found for number of LN resected, LNR, year of diagnosis, regional extent of disease, and age at diagnosis. For patients who received adjuvant RT, significant associations were found between OS and number of LN resected, number of positive resected LN, LNR, and age at diagnosis; however, extent of disease and year of diagnosis were not found to be significant prognostic factors.
An important limitation of this study includes its observational design. There are likely other potential confounders not accounted for in this data set. Margin status and use of chemotherapy may also influence outcomes, but they are not tracked in the SEER database. Similarly, assignment of RT is not randomized. As a result of these design characteristics, the associations reported need to be interpreted with appropriate cautions.
CONCLUSIONS
This review of patients' pancreatic cancer characteristics and treatment practices from the SEER database concludes LN status and extent of disease are strongly associated with survival. Age at diagnosis was significantly related with outcome, regardless of RT; thus, all models were adjusted for patient age at diagnosis. In patients not having received adjuvant RT, an earlier year of diagnosis and extension of disease outside of the pancreas were associated with worse OS in addition to fewer resected LN and LNR > 0. In patients who received adjuvant RT, only LN status (number resected, number of positive LNs, and LNR) remained statistically significantly related to OS. All patients tended to benefit from RT. A shortcoming of the SEER database, however, was that margin status and chemotherapy data were not recorded and thus could not be evaluated in this analysis.
